Rhythm Pharmaceuticals
RYTM
176 hedge funds and large institutions have $3.55B invested in Rhythm Pharmaceuticals in 2024 Q3 according to their latest regulatory filings, with 30 funds opening new positions, 62 increasing their positions, 54 reducing their positions, and 19 closing their positions.
868% more call options, than puts
Call options by funds: $46M | Put options by funds: $4.75M
58% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 19
25% more funds holding in top 10
Funds holding in top 10: 8 → 10 (+2)
25% more capital invested
Capital invested by funds: $2.85B → $3.55B (+$700M)
15% more repeat investments, than reductions
Existing positions increased: 62 | Existing positions reduced: 54
7% more funds holding
Funds holding: 165 → 176 (+11)
2.92% less ownership
Funds ownership: 113.66% → 110.75% (-2.9%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
+$30.5M |
| 2 |
HRCM
Hood River Capital Management
Palm Beach Gardens,
Florida
|
+$29.4M |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$14.4M |
| 4 |
SI
Sofinnova Investments
Menlo Park,
California
|
+$13.3M |
| 5 |
Alkeon Capital Management
New York
|
+$8.04M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$67.5M |
| 2 |
CC
Commodore Capital
New York
|
-$27.6M |
| 3 |
Pictet Asset Management
Carouge,
Switzerland
|
-$22.6M |
| 4 |
Canada Pension Plan Investment Board
Toronto Ontario,
Ontario, Canada
|
-$16.8M |
| 5 |
Nisa Investment Advisors
St. Louis,
Missouri
|
-$14.8M |
RYTM Hedge Fund Activity: Q3 2024 in Review
176 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in Rhythm Pharmaceuticals (RYTM) for Q3 2024, worth a combined $3.55B — up 25% from $2.85B a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new RYTM positions and 19 closed out — a net gain of 11 holders — while 62 added to existing stakes and 54 trimmed.
The largest buyer was Loomis, Sayles & Company, opening a new position worth an estimated $30.5M. The largest seller was Goldman Sachs, cutting an estimated $67.5M.
- 176 institutional investors held Rhythm Pharmaceuticals (RYTM) as of Q3 2024, up from 165 in Q2 2024.
- Funds reported $3.55B of Rhythm Pharmaceuticals stock for Q3 2024, up 25% quarter-over-quarter.
- 30 funds opened new Rhythm Pharmaceuticals positions in Q3 2024 and 19 closed out, a net change of +11 holders.
- The largest Rhythm Pharmaceuticals buyer in Q3 2024 was Loomis, Sayles & Company, an estimated $30.5M added.
- The largest Rhythm Pharmaceuticals seller in Q3 2024 was Goldman Sachs, an estimated $67.5M sold.
Based on aggregated 13F filings for Q3 2024.